<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917825</url>
  </required_header>
  <id_info>
    <org_study_id>P12-06</org_study_id>
    <nct_id>NCT01917825</nct_id>
  </id_info>
  <brief_title>A Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy</brief_title>
  <official_title>An Open-Label, Sequential, Dose Escalation Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this clinical trial are to investigate the pharmacokinetics and
      safety of MDT-15 pellets in escalating sequential doses administered to different cohorts.
      Preliminary efficacy data will also be collected for assessment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>364 days</time_frame>
    <description>Incidence of Adverse Events as a Measure of Safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Radicular Leg Pain</measure>
    <time_frame>Baseline and 364 days</time_frame>
    <description>Radicular leg pain measured by a 0-10 Numeric Rating Scale (NRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Function</measure>
    <time_frame>Baseline and 364 days</time_frame>
    <description>Physical Functioning measured by the Modified Roland Disability Questionnaire (RMS-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Back Pain</measure>
    <time_frame>Baseline and 364 days</time_frame>
    <description>Back pain measured by a 0-10 Numeric Rating Scale (NRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropathic Type Symptoms</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Neuropathic Type Symptoms as measured by the Short-form McGill Pain Questionnaire (SF-MPQ-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medical Outcomes study - Sleep Scale</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Sleep as measured by the Medical Outcomes Study - Sleep Scale (MOS-Sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Emotional Function</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Emotional functioning as measured by the Profile of Mood States - Brief Form (POMS- Brief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Function</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Work Function as measured by the Work Limitations Questionnaire (WLQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Rating of Improvement</measure>
    <time_frame>84 days</time_frame>
    <description>Global rating of improvement as measured by a Patient Global Impression of Change (PGIC).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Sciatica</condition>
  <condition>Lumbosacral Radiculopathy</condition>
  <arm_group>
    <arm_group_label>MDT-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDT-15</intervention_name>
    <arm_group_label>MDT-15</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be male or female at least 18 years of age.

          2. Have radiating pain toward the buttock down to the leg and/or feet, unilateral.

          3. Have radiologic pathology change from L1 - S1 consistent with a disc protrusion,
             non-sequestered extrusion, or sequestered fragment, as evidenced by magnetic resonance
             imaging (MRI), that is consistent with the clinical signs and symptoms of lumbar
             radiculopathy. The MRI must have been performed within 2 months prior to screening or
             it will need to be repeated.

          4. Have primary leg pain with an average NRS score equal to or greater than 5 as measured
             twice a day for five days in each of two weeks during screening.

          5. Have failed conservative care for at least 6 weeks. The subject must have been treated
             non-operatively (e.g., bed rest, physical therapy, medications, TENS, and/or
             manipulation) for a period of at least 6 weeks.

          6. Be willing to stop current anti-inflammatory therapy taken for treatment of radicular
             pain.

          7. Be willing and able to keep a diary that will record study-related information.

          8. If sexually active female of childbearing potential, be willing to use an acceptable
             method of birth control during the study. Acceptable methods include oral
             contraceptives (the pill), IUDs, contraceptive implants under the skin, contraceptive
             rings or patches or injections, diaphragms with spermicide, and condoms with
             spermicide. Surgical sterilization by tubal ligation or hysterectomy is acceptable.
             Women of child bearing potential are defined as women who are &lt;12 months since their
             last menstrual cycle prior to screening and have not experienced surgical menopause.

          9. Be able to understand the study and provide written informed consent.

        Exclusion Criteria:

          1. Have a history of lumbar surgery, including vertebroplasty and kyphoplasty.

          2. Be ≤ 6 weeks after lumbar ESI or nerve block at start of screening.

          3. Have current radicular pain for more than 6 months.

          4. Have more than one epidural steroid injection at the affected level to be treated
             within the last 6 months.

          5. Have demonstrated radiographic changes consistent with subject's symptoms at more than
             one level on the baseline MRI.

          6. Have symptomatic spinal stenosis of central origin at any level based on CT myelogram
             or MRI.

          7. Have pain that is localized in the lower back or other sites and is a greater
             component of the subject's total pain than the pain in the lower leg and/or foot.

          8. Have physical problems that may interfere with any study assessments.

          9. Have known infection with human immunodeficiency virus, hepatitis B virus, or
             hepatitis C virus.

         10. Have presence of local or systemic malignant disease or history of local or systemic
             malignant disease in the past 5 years (history of basal cell carcinoma will be
             allowed).

         11. Have impaired renal function (creatinine &gt;1.5 times upper limit of normal).

         12. Have chronic impairment liver function (aspartate aminotransferase [AST] or alanine
             aminotransferase [ALT] &gt;3 times upper limit of normal).

         13. Have insulin-dependent diabetes or uncontrolled diabetes mellitus (glycosylated
             hemoglobin [HbA1c] &gt;7%).

         14. Have leukopenia (&lt;3,500 leukocytes/uL).

         15. Have current orthostatic hypotension (defined as systolic blood pressure decrease of
             at least 20 mmHg or a diastolic blood pressure decrease of at least 10 mmHg or an
             increase in heart rate by 20 beats per minute within 3 minutes of standing).

         16. Have clinically significant risk for hypotension (e.g., hypotension defined as
             systolic reading &lt;90 mmHg and/or diastolic &lt;60 mmHg, hypovolemia, autonomic
             neuropathy, or other medical conditions affected by changes in blood pressure).

         17. Any clinically significant cardiovascular condition as evidenced by physical exam,
             medical history and/or baseline electrocardiogram (ECG).

         18. Have evidence of bradycardia as shown by heart rate of &lt;60 beats per minute via
             screening ECG.

         19. Have any poorly-controlled or serious medical condition, psychiatric illness, or
             clinically significant laboratory value that, in the opinion of the investigator,
             could compromise the safety of the subject or the scientific integrity of the study
             (e.g., uncontrolled hypertension, autoimmune disease, or clinically relevant symptoms
             of thyroid dysfunction).

         20. Have cauda equina syndrome.

         21. Have neurological deficits, as determined by the investigator, which would interfere
             with the assessments required by the protocol.

         22. Have been previously diagnosed with peripheral neuropathy.

         23. Have vascular claudication, as determined by the investigator, which would interfere
             with the assessments required by the protocol.

         24. Have a history or evidence of bleeding disorder (e.g., hemophilia, disseminated
             intravascular coagulation disorder [DIC], or thrombocytopenia [TCP])

         25. Have greater than 3 mm spondylolisthesis at the affected level.

         26. Have BMI greater than or equal to 40, or with any anatomic issues that may interfere
             with placement of the MDT-15 pellets as noted by the Investigator.

         27. Have a diagnosis of major depression.

         28. Have sustained a vertebral or hip fracture within the last year.

         29. Have known or suspected allergy or hypersensitivity to clonidine, lidocaine, contrast
             media, opioids, any medication that may be given as part of the site's standard of
             care related to the study drug implantation procedure, or any other medication that
             may be given as treatment during the study.

         30. Have a known or suspected allergy to polylactic acid (found in products such as Lupron
             Depot®, Atridox®, some types of dermal fillers, and some types of sutures).

         31. If female, be pregnant or breastfeeding, or desiring to become pregnant during the
             trial.

         32. Have taken an investigational drug or used an investigational device within the past
             30 days or intending to use an investigational drug or device during the trial.

         33. Have active alcoholism or drug dependency, as determined by the investigator

         34. Be currently on worker's compensation or in litigation related to injury or medical
             condition.

         35. Be in circumstances which make it difficult to maintain a usual nighttime sleep
             schedule (e.g., the subject works on an evening/night shift or otherwise has a work or
             activity schedule which could confound or interfere with study assessments).

         36. Have current treatment with any of the following medications:

               1. Systemic corticosteroids (intranasal/inhaled steroids are acceptable).

               2. Immunosuppressant therapy to treat autoimmune diseases (e.g., rheumatoid
                  arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus,
                  sarcoidosis, focal segmental glomerulosclerosis, Crohn's disease, Behcet's
                  Disease, pemphigus, and ulcerative colitis).

               3. Oral or topical products that contain clonidine (e.g., Catapres).

               4. Herbal supplements that contain yohimbine.

               5. Anti-coagulant therapy (prophylactic aspirin at 81mg/day is acceptable). If
                  applicable, aspirin therapy should be held before and after the study procedure
                  based on the investigator's discretion.

               6. Calcium channel blocker, digoxin, or beta-adrenergic blockers.

         37. Have chronic use of opioids (including tramadol), defined as use 20 out of the last 30
             days prior to study screening.

         38. Have emotional or health concerns (in the judgment of the investigator) that may
             compromise the safety of the subject, may make compliance difficult, or may confound
             the reliability of information acquired in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Holy Cross Orthopedic Institute</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St Francis Pain and Spine Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otrimed Clinical Research</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain and Rehabilitation Specialists</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <disposition_first_submitted>April 19, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 20, 2017</disposition_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radicular pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

